Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioVentrix Continues Battle To Remodel Post-Attack Hearts

Executive Summary

Following reimbursement approval in Germany, BioVentrix is making headway in long-neglected post-heart attack treatments.

You may also be interested in...



Start-Up Spotlight: BioVentrix Expects Revivent TC Heart Failure Device To Succeed Where Others Failed

Two-year data from a European trial showed BioVentrix’s Revivent TC system significantly reduces left-ventricular volume and improves left-ventricular function in patients with heart failure following a myocardial infarction. The company expects to complete a US pivotal trial of the device in 2021 and launch the device in the US with funding from a planned initial public offering.

BioVentrix: Reshaping Heart Failure

BioVentrix Inc. is developing a unique, minimally invasive approach to reshaping the heart’s scarred and enlarged left ventricle aimed at patients who develop ischemic heart failure following a heart attack. The company has made considerable headway with its technology, which offers an interesting balance between a catheter-based and surgical-based procedure; however, CEO Kenneth Miller, well aware of the pitfalls that have plagued earlier companies in this field, is taking a cautious approach to the US market.

Prescience Point Capital Launches Proxy Fight To Change MiMedx's Board

Prescience Point Capital is trying to reshuffle the board of directors leading regenerative medicine company MiMedx, arguing the company’s current board has destroyed shareholder value. The company's tock is selling for about a third of its potential value, according to Prescience.

Topics

UsernamePublicRestriction

Register

MT143605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel